SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cambridge Antibody Technology Group
An SI Board Since December 1999
Posts SubjectMarks Bans
625 23 0
Emcee:  Jongmans Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
250Abbott Laboratories Seeks U.S. and European Regulatory Approvals For Rheumatoid nigel bates-4/9/2002
249No snickering here. Appreciate your thoughts. I've been looking (and loJFitnich-3/27/2002
248I am in the process of reacquainting myself with my investments. I have a bad hkeokalani'nui-3/27/2002
247I guess they are hoping the stock price continues to improve... MELBOURN, Englanigel bates-3/12/2002
246Scios TGF-beta receptor inhibitor program - Message 17180305nigel bates-3/11/2002
245The CAT PR (are they flogging a dead horse on this one ?) - MELBOURN, England, nigel bates-3/11/2002
244U.S. Court Rules MorphoSys Does Not Infringe Griffiths Patent MARTINSRIED, Germnigel bates-3/11/2002
243Cambridge Antibody Technology Announces The Share Exchange Ratio For Its Offer Tnigel bates-3/8/2002
242Reported from the Independent - which is usually pretty accurate - "...UK nigel bates-3/7/2002
241Thanks, understand your point, and agree you are probably right about free accesaknahow-2/26/2002
240To re-iterate, the PR was released by Morphosys, not Xoma. Any "message'nigel bates-2/26/2002
239Nigel, I have read the full release and even the follow up release several timesaknahow-2/26/2002
238<i>Seems like a poor use of words to me. Apparently Xoma chose the words tnigel bates-2/26/2002
237Genomeweb comment - <i>...Biopharmaceuticals? Hold on a moment. Back in nigel bates-2/26/2002
236MorpoSys does not have a "sole" license to the Xoma technology. It isaknahow-2/26/2002
235He was CEO of Bespak in the U.K., a manufacturer of drug inhalers. Looks like tJFitnich-2/25/2002
234from >>cached<< [Still doesn't answer the questions, althoughkeokalani'nui-2/25/2002
233<i>Nigel, do you have any insight into this? </i> Hi Wilder, Not ynigel bates-2/25/2002
232In the context of the length of time it took to fill this position, some questiokeokalani'nui-2/25/2002
231Melbourn, U.K., Feb. 25 /PRNewswire-FirstCall/ -- Cambridge Antibody Technology nigel bates-2/25/2002
230Standby for more litigation ? Message 17107521 <i>MorphoSys and XOMA Cronigel bates-2/25/2002
229interesting snippet - <i>The cost of the Incyte LifeSeq® Gold databanigel bates-2/25/2002
228Cambridge Antibody Technology Group plc ('CAT') Announces First Quarter nigel bates-2/25/2002
227Just parking a couple of bits of old stuff - Licence obligations (other than DRnigel bates-2/5/2002
226Interesting <i>Drug Royalty has a royalty interest in the worldwide salesjayhawk969-1/17/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News